Immune Mediated Vaccines

Patients with safe interceded incendiary ailments (IMID, for example, RA, IBD or psoriasis, are at augmented danger of contamination, in part in light of the malady itself, however for the most part in light of treatment with immunomodulatory or immunosuppressive medications. Regardless of their raised hazard for immunization preventable ailment, inoculation scope in IMID patients is shockingly low.

  • Central nervous system-targeted & Tissue-specific autoimmunity
  • Innate immunity and diabetes vaccines
  • Vaccination strategy in patients with IMID
  • Vaccine safety: impact on disease activity in IMID patients
  • Vaccines for autoimmune skin disorders & neuropathies
  • Vaccines for immunodeficiency diseases

Related Conference of Immune Mediated Vaccines

February 27-28, 2025

8th International Conference on Vaccines and Immunology

Paris, France
April 10-11, 2025

5th International Conference on Vaccine Research

Dubai, UAE
April 22-23, 2025

8th International Conference on Vaccines, Immunology and Clinical Trials

Paris, France
April 28-29, 2025

2nd Global Summit on Vaccines & Emerging Diseases

Bali, Indonesia
May 05-06, 2025

45th Global Summit and Expo on Vaccines & Immunology

Rome, Italy
July 28-29, 2025

43rd Euro Global Summit and Expo on Vaccines & Vaccination

Aix-en-Provence, France
September 18-19, 2025

7th World Congress on Vaccine and Immunology

Amsterdam, Netherlands
October 06-07, 2025

37th Annual Congress on Vaccine and Clinical Trials

Vancouver, Canada

Immune Mediated Vaccines Conference Speakers

    Recommended Sessions

    Related Journals

    Are you interested in